This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.
The optimism seen throughout last week is clearly fading as we fast approach December, which is expected to see the Federal Reserve hike rates. While the European Central Bank could also take contrasting action to soften the blow of any rate hike, the rally we have been seeing in the US dollar has led to yet another commodities rout, which will no doubt put a bearish tone on the FTSE in coming weeks.
While supermarkets have led the FTSE lower today, we are once more looking at gains for many defence and security stocks, with BAE Systems, Cobham and Rolls-Royce part of a very exclusive list of gainers today. Following the Paris attacks, we are seeing a clear shift away from austerity and instead towards expansion of military capabilities, which will ultimately benefit defence manufacturers more than most.
Buy the rumour, sell the fact was proven to be the case today when Allergan and Pfizer announced they will merge to create of the world’s biggest drugmaker in the second half of 2016. Despite today’s fall in the share price, the firm stands in good stead to dominate the sector going forward, and long-term investors will once more take precedence over short-term speculative buyers.